Jefferies & Co Initiates Coverage on Lev Pharmaceuticals (LEVP) with a Buy
More News related to LEVP
- Rodman & Renshaw Upgrades Viropharma (VPHM) to Market Outperform
- Jefferies Downgrades Lev Pharmaceuticals (LEVP) to Hold
- Notable Mergers and Acquisitions of the Day 7/15 (VPHM/LEVP, ETFC/BNS, MOS)
- ViroPharma (VPHM) To Acquire Lev Pharmaceuticals (LEVP) For $442.9 Million
- Jefferies & Co Initiates Coverage on Lev Pharmaceuticals (LEVP) with a Buy
More News related to New Coverage
- After-Hours Movers 11/30: GES, ALTR Higher; NLST, CUTR, LTON, OVTI Lower
- Trading Radar for 12/1: Staples (SPLS), Universal Tech (UTI), Beacon Roofing (BECN) Report
- Unusual 11 Mid-Day Movers 11/30: SOMX, CLWT, KBX, CSGS Higher; AIG, BGP, BONT, HEB Lower
- Notable ETF Movers: SLX, EWJ, USO Higher; UNG, XRT Lower
- Best of the Web 11/30: Some Banks So Bad Buyers Won't Touch 'Em, Risky Bets Hurt Harvard, Eurozone Inflation Turns Positive
Jefferies & Co initiates coverage on Lev Pharmaceuticals (OTCBB: LEVP) with a Buy, citing positive growth outlook. Price target $3.
Lev Pharmaceuticals, Inc. is a development- stage biopharmaceutical company. The Company was established to develop and commercialize therapeutic products for the treatment of inflammatory diseases.
Related Categories
New CoverageStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
